Medication-Related Osteonecrosis of the Jaw—A Continuing Issue
Source abstract
Abstract
Introduction: Medication-related osteonecrosis of the jaw (MRONJ) is a condition that is becoming more common in the everyday practice of both dental and maxillofacial surgeons. Materials and methods: This paper aims to provide a comprehensive and easy to read by clinicians presentation of comprehensive, accessible, and up-to-date data on MRONJ. The individual chapters focus on the etiology, epidemiology, diagnosis, prevention, treatment, and recurrence of MRONJ. Results and discussion: It has been observed over the years that among drugs that increase the risk of the disease, apart from bisphosphonates, angiogenesis inhibitors and anti-RANKL monoclonal antibodies should also be included. A thorough physical and subjective examination, periodic correction of dental prostheses, and an adequate preparation for even the simplest of procedures in the oral cavity area can prevent or minimize the risk of MRONJ. Conclusions: It is extremely difficult to treat once it occurs and oftentimes is a recurring problem that leads to a multitude of symptoms that gradually decrease the quality of a patient’s life.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Bone health and treatments · Bone and Joint Diseases · Cancer Diagnosis and Treatment
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Maxillofacial Surgery, Hospital of the Ministry of Interior, Wojska Polskiego 51, 25-375 Kielce, Poland
Department of Biochemistry and Medical Chemistry, Pomeranian Medical University, Powstańców Wielkopolskich 72, 70-111 Szczecin, Poland
Preventive Medicine Center, Komorowskiego 12, 30-106 Kraków, Poland
Non-Public Healthcare Center for Dentistry, Maxillofacial Surgery and Implantology “Ars Medica”, Zagórska 20/15-16, 25-355 Kielce, Poland
References (58)
Show source-provided references
1. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: A growing epidemic10.1016/S0278-2391(03)00720-1 ↗
2. American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw—2014 update10.1016/j.joms.2014.04.031 ↗
3. Current Understanding of the Osteonecrosis of the Jaw10.1007/s11914-018-0474-4 ↗
4. Bisphosphonates: Mechanism of action and role in clinical practice10.4065/83.9.1032 ↗
5. Bisphosphonates and other bone agents for breast cancer
6. New therapeutic opportunities for COVID-19 patients with Tocilizumab: Possible correlation of interleukin-6 receptor inhibitors with osteonecrosis of the jaws10.1016/j.oraloncology.2020.104659 ↗
7. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy10.1359/jbmr.090716 ↗
8. Medication-related osteonecrosis of the jaws (MRONJ) review: What Irish dentists need to know, from international guidelines to current controversies
9. Medication-Related Osteonecrosis of the Jaws (MRONJ): Etiological update
10. Autologous platelet-rich fibrin injections in the management of facial cutaneous sinus tracts secondary to medication-related osteonecrosis of the jaw10.1111/dth.13334 ↗
11. Pacjenci z MRONJ: Doświadczenia własne
12. Workshop of European task force on medication-related osteonecrosis of the jaw-Current challenges10.1111/odi.13160 ↗
13. Incidence of medication-related osteonecrosis of jaw in patients treated with both bone resorption inhibitors and vascular endothelial growth factor receptor tyrosine kinase inhibitors10.1007/s00520-017-3903-5 ↗
14. Positionspapier zur medikamentenassoziierten Osteonekrose des Kiefers (MRONJ) [Position paper on medication-related osteonecrosis of the jaw (MRONJ)]10.1007/s10354-016-0437-2 ↗
15. The Frequency of Medication-related Osteonecrosis of the Jaw and its Associated Risk Factors10.1016/j.coms.2015.06.003 ↗
16. Numb chin syndrome: A reflection of malignancy or a harbinger of MRONJ? A multicenter experience10.1016/j.jormas.2018.04.006 ↗
17. The Role Of Imaging In Mronj: An Evidence Based, Institutional Experience10.1016/j.oooo.2020.03.009 ↗
18. Volumetric analysis of MRONJ lesions by semiautomatic segmentation of CBCT images10.1007/s10006-019-00805-x ↗
19. Cross-Sectional Study of four Serological Bone Turnover Markers for the Risk Assessment of Medication-Related Osteonecrosis of the Jaw10.1097/SCS.0000000000004224 ↗
20. Value of pre-operative CTX serum levels in the prediction of medication-related osteonecrosis of the jaw (MRONJ): A retrospective clinical study10.1007/s13167-019-0160-3 ↗
21. A Drug Holiday Reduces the Frequency and Severity of Medication-Related Osteonecrosis of the Jaw in a Minipig Model10.1002/jbmr.4119 ↗
22. Oral risk factors associated with medication-related osteonecrosis of the jaw in patients with cancer10.1007/s00774-020-01195-x ↗
23. Campisi, G. (2018). New paradigms for dental prevention of medication related osteonecrosis of jaws (MRONJ). Qeios.10.32388/652365 ↗
24. Dental implants as risk factors for patients with medication-related osteonecrosis of the jaws (MRONJ)10.1016/j.bjoms.2020.03.022 ↗
25. The Dental Management of Patients at Risk of Medication-Related Osteonecrosis of the Jaw: New Paradigm of Primary Prevention
26. Polish Dental Association And National Programme To Protect Antibiotics Working Group recommendations for administration of antibiotics in dentistry10.5114/jos.2018.85560 ↗
27. Nica, D.F., Riviș, M., Roi, C.I., Todea, C.D., Duma, V.F., and Sinescu, C. (2021). Complementarity of Photo-Biomodulation, Surgical Treatment, and Antibiotherapy for Medication-Related Osteonecrosis of the Jaws (MRONJ). Medicina, 57.10.3390/medicina57020145 ↗
28. Surgical Management of Medication-Related Osteonecrosis of the Jaw Patients Related to Dental Implants10.1097/SCS.0000000000006283 ↗
29. Peri-implant MRONJ
30. Surgical therapy for bisphosphonate-related osteonecrosisof the jaw: Six-year experience of a single institution10.1016/j.joms.2015.01.008 ↗
31. Medication-related osteonecrosis of the jaw: Surgical or non-surgical treatment?10.1111/odi.12764 ↗
32. Treatment of medication-related osteonecrosis of the jaws (MRONJ) with ultrasonic piezoelectric bone surgery. A case series of 20 treated sites10.1007/s10006-016-0597-7 ↗
33. Stage 3 medicationrelated osteonecrosis of the posterior maxilla: Surgical treatment using a pedicled buccal fat pad flap: Case reports10.1016/j.joms.2015.06.165 ↗
34. Evaluation of surgical outcome and influencing risk factors in patients with medication-related osteonecrosis of the jaws10.1016/j.jcms.2016.08.001 ↗
35. Bisphosphonate-related osteonecrosis of the jaws: Cohort study of surgical treatment results in seventy-four stage II/III patients10.1016/j.jcms.2016.06.016 ↗
36. Microsurgical Reconstruction of the Jaws Using Vascularised Free Flap Technique in Patients with Medication-Related Osteonecrosis: A Systematic Review10.1155/2018/9858921 ↗
37. Medication-related osteonecrosis (MRONJ) of the mandible and maxilla10.1136/bcr-2018-224455 ↗
38. Free flap reconstruction for patients with bisphosphonate related osteonecrosis of the jaws after mandibulectomy10.1016/j.jcms.2015.11.015 ↗
39. Surgical resection and vascularized bone reconstruction in advanced stage medication-related osteonecrosis of the jaw10.1016/j.ijom.2017.01.023 ↗
40. Microsurgical reconstruction after bisphosphonate-related osteonecrosis of the jaw, our experience with fibula free flap10.1097/SCS.0000000000000833 ↗
41. Medication-related osteonecrosis of the jaw (MRONJ) stage III: Conservative and conservative surgical approaches versus an aggressive surgical intervention: A systematic review10.1016/j.jcms.2020.02.017 ↗
42. Une opportunité en paro-implantologie: Le PRF
43. Does the Addition of Bone Morphogenetic Protein 2 to Platelet-Rich Fibrin Improve Healing After Treatment for Medication-Related Osteonecrosis of the Jaw?10.1016/j.joms.2016.12.005 ↗
44. Can platelet-rich fibrin improve healing after surgical treatment of medication-related osteonecrosis of the jaw? A pilot study10.1016/j.oooo.2018.06.007 ↗
45. Is the application of platelet concentrates effective in the prevention and treatment of medication-related osteonecrosis of the jaw? A systematic review10.1016/j.jcms.2020.01.014 ↗
46. Can Autofluorescence Guide Surgeons in the Treatment of Medication-Related Osteonecrosis of the Jaw? A Prospective Feasibility Study10.1016/j.joms.2017.10.024 ↗
47. Imaging modalities for drug-related osteonecrosis of the jaw (3), Positron emission tomography imaging for the diagnosis of medication-related osteonecrosis of the jaw10.1016/j.jdsr.2018.12.001 ↗
48. Preventive Effect of Phosphodiesterase Inhibitor Pentoxifylline Against Medication-Related Osteonecrosis of the Jaw: An Animal Study10.1016/j.joms.2017.04.017 ↗
49. deficiency a risk factor for osteonecrosis of the jaw in patients with cancer? A matched case-control study10.1016/j.jcms.2019.03.007 ↗
50. Vitamin D supplementation: Hypothetical effect on medication-related osteonecrosis of the jaw10.1016/j.mehy.2018.04.023 ↗
51. Dalle Carbonare, L., Mottes, M., and Valenti, M.T. (2021). Medication-Related Osteonecrosis of the Jaw (MRONJ): Are Antiresorptive Drugs the Main Culprits or Only Accomplices? The Triggering Role of Vitamin D Deficiency. Nutrients, 13.10.3390/nu13020561 ↗
52. Treatment of bisphosphonate-related osteonecrosis of the jaws—A report of seven cases10.5114/wo.2016.65610 ↗
53. Panaś, M., Zaleska, M., and Kaczmarzyk, T. (2012). Osteonecrosis of the Jaw Involving Bisphosphonate Treatment for Osteoporosis. IntechOpen.10.5772/31089 ↗
54. Czy ekstrakcje zębów u pacjentów w trakcie terapii bisfosfonianami są przeciwskazane?
55. Martwica kości szczęk w wyniku stosowania bisfosfonianów. Przegląd piśmiennictwa
56. Evaluation of the Treatment Strategies for Medication-Related Osteonecrosis of the Jaws (MRONJ) and the Factors Affecting Treatment Outcome: A Multicenter Retrospective Study with Propensity Score Matching Analysis10.1002/jbmr.3191 ↗
57. Prophylaxis of medication-related necrosis of the jaws in dental patients—Study of 49 cases10.26444/jpccr/94396 ↗
58. Clinical characteristics and recurrence-related factors of medication-related osteonecrosis of the jaw10.5125/jkaoms.2018.44.5.225 ↗